Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

Published:2021-08 Issue:8 Volume:8 Page:e552-e561
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kadia Tapan M,Reville Patrick K,Borthakur Gautam,Yilmaz Musa,Kornblau Steven,Alvarado Yesid,Dinardo Courtney D,Daver Naval,Jain Nitin,Pemmaraju Naveen,Short Nicholas,Wang Sa A,Tidwell Rebecca S S,Islam Rabiul,Konopleva Marina,Garcia-Manero Guillermo,Ravandi Farhad,Kantarjian Hagop M

Funder

NCI

Publisher

Elsevier BV

Subject

Hematology

Reference23 articles.

1. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial;Willemze;J Clin Oncol,2014

2. Cytarabine dose for acute myeloid leukemia;Löwenberg;N Engl J Med,2011

3. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis;Li;PLoS One,2014

4. Acute myeloid leukemia: current progress and future directions;Kantarjian;Blood Cancer J,2021

5. High-dose daunorubicin in older patients with acute myeloid leukemia;Löwenberg;N Engl J Med,2009

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondria and Acute Leukemia: A Clinician’s Perspective;International Journal of Molecular Sciences;2024-09-07

2. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia;Leukemia & Lymphoma;2024-09-04

3. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study;Annals of Hematology;2024-08-29

4. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia;Frontiers in Immunology;2024-08-16

5. Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia;Pediatric Blood & Cancer;2024-08-16